CalciMedica (CALC)

• Market cap: $41.5M
• 1 day: -0.67%
• 5 days: -2.62%
• 1 month: -3.57%
• 3 months: -13.66%
• 6 months: 89.17%
• Year to date: -9.73%
• 1 year: -19.73%
• 5 years: -98.56%
• 10 years: -98.71%
• Sector: Healthcare
• Industry: Biotechnology

About: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Employees: 15